Artivion, Inc. (AORT)
NYSE: AORT · Real-Time Price · USD
36.33
-0.70 (-1.89%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Artivion Revenue
In the year 2025, Artivion had annual revenue of $441.33M with 13.59% growth. Artivion had revenue of $115.99M in the quarter ending December 31, 2025, with 19.20% growth.
Revenue (ttm)
$441.33M
Revenue Growth
+13.59%
P/S Ratio
3.99
Revenue / Employee
$245,183
Employees
1,800
Market Cap
1.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 441.33M | 52.79M | 13.59% |
| Dec 31, 2024 | 388.54M | 34.53M | 9.75% |
| Dec 31, 2023 | 354.00M | 40.22M | 12.82% |
| Dec 31, 2022 | 313.79M | 14.95M | 5.00% |
| Dec 31, 2021 | 298.84M | 45.61M | 18.01% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.24B |
| Enovis | 2.25B |
| Tandem Diabetes Care | 1.01B |
| Inspire Medical Systems | 911.98M |
| Neogen | 870.56M |
| Alphatec Holdings | 764.16M |
| NovoCure | 655.35M |
| UFP Technologies | 602.80M |
AORT News
- 5 days ago - Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results - PRNewsWire
- 21 days ago - Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System - PRNewsWire
- 6 weeks ago - Artivion Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference - Transcripts
- 2 months ago - Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - PRNewsWire
- 2 months ago - Artivion Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Artivion Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 3 months ago - Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting - PRNewsWire
- 3 months ago - Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results - PRNewsWire